• KOL
    • Heart Transplantation
    • Jon A Kobashigawa
    • Jon A Kobashigawa: Influence Statistics

       Jon A Kobashigawa

      Jon A Kobashigawa

      Show email address

      Cedars-Sinai Heart Institute, Los Angeles, CA, USA | Department of Cardiology, Smidt Heart Institute, Cedars‐Sinai Medical Center, Los Angeles, California, USA | Comprehensive ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Jon A Kobashigawa:Expert Impact

      Concepts for whichJon A Kobashigawahas direct influence:Heart transplantation,Heart transplant,Cardiac transplantation,Heart failure,Heart transplant recipients,United states,Mycophenolate mofetil,Transplant recipients.

      Jon A Kobashigawa:KOL impact

      Concepts related to the work of other authors for whichfor which Jon A Kobashigawa has influence:Heart transplantation,Transplant recipients,Mycophenolate mofetil,Graft rejection,Renal function,Pulmonary hypertension.

      KOL Resume for Jon A Kobashigawa

      Year
      2022

      Cedars-Sinai Heart Institute, Los Angeles, CA, USA

      Cedars Sinai Medical Center, Los Angeles, États-Unis

      2021

      Cedars-Sinai Medical Center, Los Angeles, California.

      Department of Cardiology, Cedars‐Sinai Medical Center, Smidt Heart Institute, Los Angeles, CA, USA

      2020

      Cardiology, Cedars-Sinai Health System, Los Angeles, CA

      Comprehensive Transplant Center, Cedars‐Sinai Medical Center, Los Angeles, California, USA

      Cedars-Sinai Smidt Heart Institute, Los Angeles, California.

      University of Calgary, Calgary, Canada

      2019

      1 Division of Cardiology Cedars-Sinai Smidt Heart Institute the Multiorgan Transplant Program Cedars-Sinai Medical Center Los Angeles CA.

      Cedars‐Sinai Smidt Heart Institute, Los Angeles, California

      Cedars-Sinai Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA

      2018

      Ceder‐Sinai Medical Center, Los Angeles, California

      Cedars-Sinai Heart Institute, Beverly Hills, CA

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Jon A Kobashigawa is among the top experts in the world.
      Concept World rank
      100 months freedom #1
      average percent stenosis #1
      outcome benefits heart #1
      immunologic matching #1
      lumen loss 20 #1
      angiographic cardiac vasculopathy #1
      achd current #1
      impact firstyear #1
      cpra 0 #1
      bnr rejection #1
      dsa htx #1
      underwent htx #1
      rejection ecv #1
      durable circulatory support #1
      transplant gep #1
      challenges immunosuppression #1
      cholesterol levels survival #1
      long qt cav #1
      mcs bridging mcs #1
      cardiac rejection influence #1
      cardiac transplantation cav #1
      acei ramipril #1
      cav bms #1
      sensitized patients trend #1
      transplantation 2004 #1
      fatal major #1
      rejection mild #1
      retransplantation cav #1
      nps prior sternotomy #1
      cav survival #1
      dmcs heart transplantation #1
      cellular prognosis receptor #1
      mpa dose ecmps #1
      p0001 lower hrqol #1
      ivus increased prevalence #1
      medical marijuana transplant #1
      durable mcs transplantation #1
      panel nmdpcpra #1
      sensitized mcs #1
      marijuana listing #1
      dm 816 #1
      heart transplant community #1
      vivo vivo cdti #1
      subsequent heart transplantation #1
      → dmcs patients #1
      dsa heart transplantation #1
      donor specific antibody #1
      organ 207 ± #1
      cmv aza #1
      match virtual #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Jon A Kobashigawa

      KOL-Index: 15326

      BACKGROUND: The calcineurin inhibitors (CNIs), cyclosporine and tacrolimus, have had a revolutionary effect on the overall success of renal transplantation through reduction in early immunologic injury and acute rejection rates. However, the CNIs have a significant adverse impact on renal function and cardiovascular disease, and extended long-term graft survival has not been achieved. The recognition of these effects sparked interest in CNI-sparing strategies. Strategies to limit CNI ...

      Known for Renal Function | Cni Minimization | Mycophenolate Mofetil | Solid Organ Transplantation | Calcineurin Inhibitors
      KOL-Index: 15180

      BACKGROUND: Historically, panel reactive antibody (PRA) analysis to detect HLA antibodies has been performed using cell-based complement-dependent cytotoxicity (CDC) techniques. Recently, a flow cytometric procedure (FlowPRA) was introduced as an alternative approach to detect HLA antibodies. The flow methodology, using a solid phase matrix to which soluble HLA class I or class II antigens are attached is significantly more sensitive than CDC assays. However, the clinical relevance of ...

      Known for Patients Antibodies | Cytometric Detection | Graft Rejection | Pretransplant Hla | Class Antigens
      KOL-Index: 14645

      The most advantageous combination of immunosuppressive agents for cardiac transplant recipients has not yet been established. Between November 2001 and June 2003, 343 de novo cardiac transplant recipients were randomized to receive steroids and either tacrolimus (TAC) + sirolimus (SRL), TAC + mycophenolate mofetil (MMF) or cyclosporine (CYA) + MMF. Antilymphocyte induction therapy was allowed for up to 5 days. The primary endpoint of >/=3A rejection or hemodynamic compromise rejection ...

      Known for Mycophenolate Mofetil | Cardiac Transplant Patients | Tac Mmf | 1 Year | Immunosuppressive Agents
      KOL-Index: 14601

      BACKGROUND: Enteric-coated mycophenolate sodium (EC-MPS, myfortic) is an advanced formulation that delays the release of mycophenolic acid (MPA). Its efficacy and safety has been proven in several clinical trials in renal transplantation.

      METHODS: In a single-blind, multicenter trial, a total of 154 de novo heart transplant patients were randomized to either EC-MPS 1,080 mg twice daily or mycophenolate mofetil (MMF) 1,500 mg twice daily. Eligible patients included men or women aged 18 to ...

      Known for Ecmps Mmf | Mycophenolate Mofetil | Transplant Recipients | Treatment Failure | 12 Months
      KOL-Index: 14537

      BACKGROUND: The goal of this study was to determine whether antidonor antibodies directed against human leukocyte antigen (HLA) or endothelial cells (ECs) expressed antigens, including major histocompatibility complex class I chain-related antigens A (MICA) are associated with the diagnosis of antibody-mediated rejection (AMR) in heart transplant recipients.

      METHODS: We studied posttransplant antidonor HLA antibodies in 168 heart allograft recipients transplanted from October 2001 to ...

      Known for Heart Transplantation | Hla Mica | Endothelial Cells | Patients Dsa | Mediated Rejection
      KOL-Index: 13924

      BACKGROUND: Everolimus, a novel proliferation inhibitor and immunosuppressive agent, may suppress cardiac-allograft vasculopathy. We conducted a randomized, double-blind, clinical trial comparing everolimus with azathioprine in recipients of a first heart transplant.

      METHODS: A total of 634 patients were randomly assigned to receive 1.5 mg of everolimus per day (209 patients), 3.0 mg of everolimus per day (211 patients), or 1.0 to 3.0 mg of azathioprine per kilogram of body weight per ...

      Known for Everolimus Azathioprine | Allograft Rejection | Incidence Vasculopathy | Transplant Recipients | Primary Efficacy Point
      KOL-Index: 13003

      OBJECTIVES: A pre-planned substudy of a larger multicenter randomized trial was undertaken to compare the efficacy of everolimus with reduced-dose cyclosporine in the prevention of cardiac allograft vasculopathy (CAV) after heart transplantation to that of mycophenolate mofetil (MMF) with standard-dose cyclosporine.

      BACKGROUND: CAV is a major cause of long-term mortality following heart transplantation. Everolimus has been shown to reduce the severity and incidence of CAV as measured by ...

      Known for Intravascular Ultrasound | Cardiac Allograft Vasculopathy | Mycophenolate Mofetil | Heart Transplantation | Cav Everolimus
      KOL-Index: 12318

      OBJECTIVES: We sought to compare percutaneous coronary intervention (PCI) with bare-metal stents (BMS) and drug-eluting stents (DES) for cardiac allograft vasculopathy (CAV).

      BACKGROUND: Cardiac allograft vasculopathy is a rapidly progressive form of atherosclerosis and is one of the main limitations to long-term survival after orthotopic heart transplantation. Percutaneous coronary intervention has been used as a palliative treatment option for CAV but is associated with worse clinical ...

      Known for Eluting Stents | Allograft Vasculopathy | Percutaneous Coronary | Cav Bms | Heart Transplantation
      KOL-Index: 11955

      BACKGROUND: Acute cellular rejection is the mechanism of most immune-related injury in cardiac transplant recipients. However, antibody-mediated humoral rejection (HR) has also been implicated as an important clinical entity following orthotopic heart transplantation. Humoral rejection has been reported to play a role in graft dysfunction in the early post-transplant period, and to be a risk factor for the development of transplant coronary artery disease. Some involved in ...

      Known for Humoral Rejection | Coronary Artery | Cardiac Transplantation | Graft Dysfunction | Pathologic Diagnosis
      KOL-Index: 11865

      BACKGROUND: Hypercholesterolemia is common after cardiac transplantation and may contribute to the development of coronary vasculopathy. Pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, has been shown to be effective and safe in lowering cholesterol levels after cardiac transplantation. Cell-culture studies using inhibitors of HMG-CoA reductase have suggested an immunosuppressive effect.

      METHODS: Early after transplantation, we randomly assigned ...

      Known for Cardiac Transplantation | Coronary Vasculopathy | Pravastatin Control | Cholesterol Levels | Hemodynamic Compromise
      KOL-Index: 11427

      INTRODUCTION: Patients with history of prior sternotomy may have poorer outcomes after heart transplantation. Quantitation of risk from prior sternotomy has not been well established. The United Network for Organ Sharing (UNOS) database was analyzed to assess early and late survival and predictors of outcome in adult heart transplant recipients with and without prior sternotomy.

      METHODS: Of 11,266 adults with first heart-only transplantation from 1997 to 2011, recipients were divided ...

      Known for Prior Sternotomy | Heart Transplantation | United Network | Organ Sharing Database | 2 Groups
      KOL-Index: 11387

      BACKGROUND: Although studies have provided us with a cross-sectional analysis of long-term quality of life (QOL) after transplantation, relatively few longitudinal studies have been done that allow us to understand changes in QOL over time. The purposes of our study were to describe QOL over time and identify predictors of QOL longitudinally from 5 to 10 years after heart transplantation.

      METHODS: All 555 subjects enrolled in this study completed booklets of questionnaires. These ...

      Known for 10 Years | Life Qol | Heart Transplantation | Predictors Satisfaction | Physiological Adaptation
      KOL-Index: 11363

      BACKGROUND: De novo donor HLA-specific (dnDSA) and non-HLA antibodies including antiangiotensin type 1 receptor antibodies (AT1R-abs) have been associated with antibody-mediated rejection (AMR) and decreased graft survival as well as cellular-mediated rejection (CMR) and early onset of microvasculopathy in heart transplantation. The aim of our study was to determine the impact of anti-AT1R-ab and anti-donor HLA-specific antibody (DSA) on clinical outcomes.

      METHODS: Pretransplant and ...

      Known for Graft Outcome | Increased Negative Impact | Freedom Amr | Heart Transplantation | Dsa Transplant
      KOL-Index: 11209

      Cardiac transplantation is predicted to improve survival for patients with severe symptoms of heart failure and ejection fraction of 20% or less, but the exercise capacity after cardiac transplantation is less than normal. Patients responding to vasodilators and diuretics have progressive improvement in exercise capacity despite low ejection fraction. We hypothesized that among patients currently considered appropriate for transplantation who could nonetheless subsequently be stabilized ...

      Known for Exercise Capacity | Cardiac Transplantation | Medical Therapy | Heart Failure | Ejection Fraction
      KOL-Index: 11180

      BACKGROUND: Cardiac sarcoidosis with end-stage heart failure has a poor prognosis without transplantation. The rates of sarcoid recurrence and rejection are not well established after heart transplantation.

      METHODS: A total of 19 heart transplant recipients with sarcoid of the explanted heart were compared with a contemporaneous control group of 1,050 heart transplant recipients without cardiac sarcoidosis. Assessed outcomes included 1st-year freedom from any treated rejection, 5-year ...

      Known for Heart Transplantation | Cardiac Sarcoidosis | 5 Year | Graft Rejection | Transplant Recipients

      Key People For Heart Transplantation

      Top KOLs in the world
      #1
      Jon A Kobashigawa
      heart transplantation united states mycophenolate mofetil
      #2
      Leah Bennett Edwards
      lung transplantation international society united states
      #3
      James K Kirklin
      heart transplantation ventricular assist united states
      #4
      Donna M Mancini
      heart failure cardiac transplantation ventricular assist
      #5
      Josef Stehlik
      lung transplantation heart failure international society
      #6
      David C Naftel
      heart transplantation united states interagency registry

      Cedars-Sinai Heart Institute, Los Angeles, CA, USA | Department of Cardiology, Smidt Heart Institute, Cedars‐Sinai Medical Center, Los Angeles, California, USA | Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA USA | Depa

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.